Latest Exenatide Stories
DrugRisk is the Web’s largest source for information on prescription drug warnings, side effects and legal news. Visit http://www.DrugRisk.com San Diego, CA (PRWEB) May 22, 2013 The diabetes drug safety advocates at DrugRisk.com are announcing updated information for patients taking the medication Byetta. The FDA is investigating whether drugs like this are related to cancer after a study found pre-cancerous cells present in patient deaths*. The goal of DrugRisk is to improve the safety...
Parkinson's disease (PD) is a degenerative neurological disorder marked by a progressive loss of motor control. Despite intensive research, there are currently no approved therapies that have been demonstrated to alter the progression of the disease. In this issue of the Journal of Clinical Investigation, Dr. Thomas Foltynie and colleagues at the National Hospital for Neurology and Neurosurgery in London investigated the use of a drug approved for diabetes care, Exenatide, in PD patients. PD...
Gilman Law LLP is Investigating Byetta Lawsuits on Behalf of Victims of Pancreatic Cancer Side Effects, Allegedly Associated with Byetta, Januvaia, Victoza, and other Diabetes Drugs Known as Incretin Mimetics. Boston, MA (PRWEB) May 20, 2013 Gilman Law LLP, a leading pharmacy law and defective drug plaintiffs’ law firm investigating Byetta lawsuits, is troubled by a new study that reveals that pancreatic cancer reports associated with Byetta and similar type 2 diabetes drugs are...
JERUSALEM, May 17, 2013 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that the United States Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug application(IND) for ORMD-0801, its oral insulin capsule. "We are very pleased to have the FDA clearance to proceed," stated Nadav Kidron, CEO of Oramed. "The upcoming trial is a major milestone...
DrugRisk is the Web’s largest source for information on prescription drug warnings, side effects and legal news. Visit http://www.DrugRisk.com Sacramento, CA (PRWEB) May 14, 2013 The diabetes drug safety advocates at DrugRisk.com are announcing updated information for patients who have taken the medication Byetta. The maker of the drug has agreed with moving the growing number of injury claims to a special federal court in California*. DrugRisk was created to improve the safety of those...
The firm is currently evaluating Byetta lawsuits for those who have suffered from allegedly serious Byetta side effects. (PRWEB) May 13, 2013 On May 9 a woman filed a lawsuit against drug makers Amylin Pharmaceuticals and Eli Lilly in federal court, alleging that the companies failed to adequately warn her about type 2 diabetes drug Byetta’s link to thyroid cancer, according to court documents for Childress v. Amylin Pharmaceuticals LLC, et al., No. 3:13-1114 (U.S. District Court for...
Consumer inquiries about legal rights increase after FDA announces investigation into Januvia and other diabetes drugs over research study linking medications to pancreatitis. Free legal consultations now being offered by Resource4thePeople national network of attorneys. San Diego, CA (PRWEB) May 10, 2013 http://www.resource4thepeople.com/defectivedrugs/januvia.html Resource4thePeople announced today that its attorneys are offering free legal consultations to patients who used a certain...
DrugRisk is the Web’s largest source for information on prescription drug warnings, side effects and legal news. Visit http://www.DrugRisk.com Los Angeles, CA (PRWEB) May 04, 2013 The diabetes drug safety advocates at DrugRisk.com are announcing updated information for patients who have taken the medication Byetta. A recent study suggests the drug may have higher occurrence rates of pancreatic cancer and thyroid cancer than traditional treatments. DrugRisk was created to improve the...
Study assessed effectiveness of ORMD-0801 in stabilizing blood sugar levels in unstable Type 1 diabetes patients JERUSALEM, May 1, 2013 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a developer of oral delivery systems of drugs currently administered by injection, announced today that its article titled, "Glucose-reducing effect of the ORMD-0801 oral insulin preparation in patients with uncontrolled Type 1 diabetes: a pilot study," has...
TORONTO, April 30, 2013 /PRNewswire/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) announced the results of a five-week proof of concept clinical study of TT-401 in type 2 diabetic and obese non-diabetic subjects. In the study, TT-401 a once-weekly administered peptide, demonstrated significant improvements in glycemic control and reductions in body weight. The study enrolled diabetic patients at five dosing levels and non-diabetic...
Latest Exenatide Reference Libraries
The Gila monster (Heloderma suspectum) is one of the two known species of venomous lizards. This lizard lives in the deserts of the southwestern USA and northwestern Mexico. It is a heavy, slow moving lizard and can measure up to 2 feet (60 cm) in length. Its skin has the appearance of beads in the colors black, pink, orange, and yellow, laid down in intricate patterns across the animal's body. Unlike a snake, the Gila monster envenomates its victim through grooves in the teeth of its...
